SCHEMBL19084022

SCHEMBL19084022

CC1(COc2cc(F)c(C(=O)N3CCC[C@H]3C(=O)O)cc2C2CCC2)CC=C2CC2C1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 20/20 0.43
SCN5A Q14524 5/20 0.39
SCN1A P35498 3/20 0.39
SCN2A Q99250 3/20 0.39
SCN8A Q9UQD0 3/20 0.39
SCN7A Q01118 3/20 0.39
CYP2C9 P11712 1/20 0.39
SCN2B O60939 1/20 0.38
SCN4A P35499 1/20 0.38
SCN1B Q07699 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20697639 0.90 SCN9A (0.44) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL21075495 0.87 SCN9A (0.47) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL20697924 0.85 SCN9A (0.42) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL21075252 0.84 SCN9A (0.46) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL19083703 0.83 SCN9A (0.47) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL20697918 0.83 SCN9A (0.42) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL20697624 0.83 SCN9A (0.41) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL20697628 0.83 SCN9A (0.42) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL20697678 0.83 SCN9A (0.42) SCN9ASCN5ASCN1ASCN2ASCN8A
SCHEMBL17423001 0.82 SCN9A (0.61) SCN9ASCN5ASCN1ASCN2ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 US disclosed
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-03-18 US disclosed
US-20190031607-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-01-31 US disclosed
US-10005724-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2018-06-26 US disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SCN9A 2337/4885SCN5A 1598/4885SCN1A 1166/4885
US-11149002-B2 Therapeutic compounds and methods of use thereof RDX, C1R, MTX1 SCN9A 2337/4885SCN5A 1598/4885SCN1A 1166/4885
US-20190031607-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SCN9A 2337/4885SCN5A 1598/4885SCN1A 1166/4885
US-10005724-B2 Therapeutic compounds and methods of use thereof RDX, C1R, MTX1 SCN9A 2337/4885SCN5A 1598/4885SCN1A 1166/4885
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SCN9A 2337/4885SCN5A 1598/4885SCN1A 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.